Skip to main content
OpenTrials
Completed

NCT Number: NCT03653260

A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children

The purpose of the study is to evaluate the efficacy and safety of Zingo in treating pain associated with venipunture and peripheral venous cannulation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Shanghai Children's Medical Center

Shanghai, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged 3-12
  • About to undergo venipuncture or peripheral venous cannulation at the back of the hand or antecubital fossa
  • Have sufficient cognitive skills to identify faces depicting extremes of pain on the Wong-Baker FACES scale (age 3-12) and the extremes of pain on a 100 mm visual analog scale (VAS) (ages 8-12)
  • Signed informed consent, cooperative and agree to attend follow-up visits

Exclusion criteria

  • Any medical condition, non-compliance or instability (including but not limited to exceptionally upset, crying, anxiety) that in the judgement of the investigator might adversely affect the conduct of the study
  • Used any (including external or inhaled) sedatives, analgesics, anaesthetics or other agents/device that may affect the efficacy assessment
  • Subjects with tattoos, surgical scars, ports, implantable devices or a skin condition (e.g. excessive body hair) that may have interfered with the placement of Zingo or skin site assessments
  • Active local infection or other skin pathology at the site of venipuncture or peripheral venous cannulation.
  • Venipuncture of peripheral venous cannulation at the proposed site within the prior two weeks (longer if the wound is apparent)
  • Previous history of allergic reactions to any local anaesthetic or tape/adhesive dressing.
  • Participated in a clinical trial within three months prior to administration of study drug, or have already enrolled in a Zingo clinical trial before
  • At the discretion of the investigator, any subjects that may have to be withdrawn from the study

Treatment and study plan

Lidocaine (Zingo)

Drug

0.5 mg lidocaine, 20 bar pressure

Other names: Zingo

Placebo

Drug

Placebo injector, 20 Bar pressure, empty injector

Primary outcomes

  1. Wong-Baker FACES Pain Rating Scale After Venipuncture or Peripheral Cannulation

    Time frame: immediate after venipunture

    Child's assessment of pain on venipuncture or peripheral venous cannulation (all ages) performed one to three minutes after Zingo/Placebo administration, measured using the Wong-Baker FACES pain rating scale. The scale includes pictures of facial expressions with correlating numerical scale of 0-10, 0 being no hurt and 10 being the worst hurt.

Secondary outcomes

  1. 100-mm Visual Analogue Scale (VAS)

    Time frame: immediate after venipunture

    Assessment of pain on venipuncture or peripheral venous cannulation by children age 8-12, measured using a 100-mm VAS (0-100) anchored at 0 for "no pain" and at 100 for "worst possible pain."

  2. Response Rate

    Time frame: immediate after venipunture

    Percentage of subject who score 0 or 1 in the FACES Pain Rating Scale

  3. Compliance Score

    Time frame: immediate after venipunture

    Compliance to venipuncture assess by investigator

Other outcomes

  1. Adverse Event Frequency

    Time frame: 1 day

  2. Adverse Event Severity

    Time frame: 1 day

  3. Comfort of Zingo/Placebo Administration (Wong-Baker)

    Time frame: immediate after venipunture

    Subject (all ages) to assess the level of comfort of Zingo/Placebo administration, measured using the Wong-Baker FACES scale (0-10), where 0 represent No Discomfort and 10 represent Worst Possible Discomfort.

  4. Comfort of Zingo/Placebo Administration (VAS)

    Time frame: immediate after venipunture

    Subject (age 8-12) to assess the level of comfort of Zingo/Placebo administration, measured using VAS pain rating scales (0-100), where 0 represent No Discomfort and 100 represent Worst Possible Discomfort.

  5. Local Adverse Reaction

    Time frame: Pre-dose (0-1 hour before), immediately after dose, 15 minutes, 30 minutes

    Local Adverse Reactions including erythema, edema, pruritus and hemorrhage/petechiae by severity.

Sponsors and collaborators

Lead sponsor

Lee's Pharmaceutical Limited

Industry

Collaborators

  • Zhaoke (Hefei) Pharmaceutical Limited

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety in Chinese Children

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 31, 2018
Registry last updated
Sep 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.